Santen Oy
13
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
54%
7 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
The Pattern of Dry Eye Disease After Cataract Surgery
Role: collaborator
Prevalence of Glaucoma in Belgium: a Multicenter National Trial
Role: collaborator
Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery
Role: collaborator
Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment
Role: collaborator
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing
Role: collaborator
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
Role: lead
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
Role: lead
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Role: lead
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops
Role: lead
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Role: lead
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
Role: lead
Interaction Study of Timolol Eye Drops and Paroxetine Capsules
Role: lead
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
Role: lead
All 13 trials loaded